omniture
logo
Search
QBIOTICS GROUP LIMITED
Media Room

Latest News

rss

QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA

BRISBANE, Australia, June 25, 2025 /PRNewswire/ --   QBiotics CEO, Stephen Doyle, reflecting on So...

2025-06-25 18:05 1950
QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA playbtn